Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Randomized, Double-blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Azetukalner in Depressive Episodes Associated With Bipolar I or II Disorder (Bipolar Depression)

NCT07172516 is registered in ClinicalTrials.gov with Xenon Pharmaceuticals Inc. as lead sponsor.

NCT NCT07172516
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07172516 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Randomized, Double-blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Azetukalner in Depressive Episodes Associated With Bipolar I or II Disorder (Bipolar Depression)
Lead sponsor
Xenon Pharmaceuticals Inc.
Phase
Phase 3
Overall status
Active, not recruiting
Start date
August 8, 2025
Completion date
August 31, 2028
Enrollment
400 (estimated)
Sites
44

Conditions

As the registry lists them; a condition with its own page is linked.

bipolar depression, bipolar disorder, bipolar i disorder, bipolar ii disorder